The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 03, 2019

Filed:

Oct. 11, 2016
Applicant:

Chong Kun Dang Pharmaceutical Corp., Seoul, KR;

Inventors:

Yuntae Kim, Yongin-si, KR;

Chang Sik Lee, Yongin-si, KR;

Jung Taek Oh, Yongin-si, KR;

Hyeseung Song, Yongin-si, KR;

Jin Choi, Yongin-si, KR;

Jaeyoung Lee, Yongin-si, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 271/10 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); A61K 31/4245 (2006.01); A61P 31/00 (2006.01); A61P 1/00 (2006.01); A61P 25/00 (2006.01); A61P 11/00 (2006.01); A61P 3/00 (2006.01); A61P 21/00 (2006.01); A61P 9/00 (2006.01); A61P 35/00 (2006.01); A61P 17/00 (2006.01); A61P 5/00 (2006.01); A61P 27/02 (2006.01);
U.S. Cl.
CPC ...
C07D 271/10 (2013.01); A61K 31/4245 (2013.01); A61P 1/00 (2018.01); A61P 3/00 (2018.01); A61P 5/00 (2018.01); A61P 9/00 (2018.01); A61P 11/00 (2018.01); A61P 17/00 (2018.01); A61P 21/00 (2018.01); A61P 25/00 (2018.01); A61P 27/02 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01);
Abstract

The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.


Find Patent Forward Citations

Loading…